This has recently been reported in a phase I dose escalation trial with propagermaium in patients with breast cancer [31] and a phase 2 trial with anti-MCP-1 (carlumab) in patients with idiopatic pulmonary fibrosis [32]. This evidence concerns the gene CCL2 and breast carcinoma.